Lipocine licenses Tlando testosterone therapy to Verity Pharma (NASDAQ:LPCN) – Seeking Alpha

Govind Oza/iStock via Getty Images

Lipocine (NASDAQ:LPCN) has entered a license agreement for its Tlando oral testosterone replacement therapy (TRT) with Verity Pharma.

The agreement will see Verity market Tlando in the U.S. - where it was approved in 2022 - and in Canada when it gets regulatory clearance. Verity will also hold development and commercialization rights to LPCN 1111 (Tlando XR), a "next generation" oral product candidate for TRT. It will be responsible for regulatory and marketing obligations in the U.S. and Canada.

Lipocine will get a $11M license fee and up to $259M in development and commercialization milestones. It retains rights to the Tlando franchise outside the US and Canada.

Antares Pharma - now part of Halozyme Therapeutics (HALO) - held exclusive licensing rights to Tlando at the time of the therapy's final approval by the U.S. FDA in 2022.

Shares of Lipocine (LPCN) rose as much as 12% premarket on Thursday

Read more:
Lipocine licenses Tlando testosterone therapy to Verity Pharma (NASDAQ:LPCN) - Seeking Alpha